Strategic partnership Inserm Transfert is a dedicated bridge between Inserm innovations and industry, with a proven track record of partnerships and licensing deals that can be leveraged to identify co-development and licensing opportunities with pharma, biotech, and medtech players.

Therapeutic targets Recent collaborations focus on obesity, metabolic diseases, neurovascular and neurodegenerative conditions, and NK cell therapies, signaling potential for joint research, proof-of-concept funding, and long-term development programs with external sponsors.

Funding pathways A history of early-stage funding through dedicated seed funds and proof of concept investments creates openings for clients seeking to sponsor early research, technology validation, or translational grants associated with Inserm Transfert projects.

Global collaboration Active engagement with international partners and universities, plus management of European and international projects, presents opportunities for multinational partnerships, tech transfer programs, and cross-border licensing deals.

Commercial readiness With a revenue footprint and a public service management framework, Inserm Transfert offers ready access to early-stage technologies, clinical data capabilities, and structured pathways for invention disclosures to industrial partnerships and startup formation.